Discovery of the Triazolo[1,5‑<i>a</i>]Pyrimidine-Based Derivative WS-898 as a Highly Efficacious and Orally Bioavailable ABCB1 Inhibitor Capable of Overcoming Multidrug Resistance... by Shuai Wang (109515)

“…Here, we reported our medicinal chemistry efforts that led to the discovery of the triazolo­[1,5-<i>a</i>]­pyrimidine derivative <b>WS-898</b> as a highly effective ABCB1 inhibitor capable of reversing paclitaxel (PTX) resistance in drug-resistant SW620/Ad300, KB-C2, and HEK293/ABCB1 cells (IC₅₀ = 5.0, 3.67, and 3.68 nM, respectively), more potent than verapamil and zosuquidar. …”

Compatible pollen triggers a decrease in S-RNase transcript levels by a post-transcriptional mechanism. by Bolin Liu (59887)

Fully Transparent and Rollable Electronics by Mallory Mativenga (1681909)

“…For handling purposes, carrier glass is used during fabrication, together with a very thin (∼1 nm) solution-processed carbon nanotube (CNT)/graphene oxide (GO) backbone that is first spin-coated on the glass to decrease adhesion of the CPI to the glass; peel strength of the CPI from glass decreases from 0.43 to 0.10 N/cm, which eases the process of detachment performed after device fabrication. …”

A hypoglycaemic <i>milieu</i> decreases NCS viability in a dose-dependent manner. by Shiva Mansouri (2838086)

FASN inhibitors result in decreased ΔΨm and increased superoxide production in melan-a cells. by Franco A. Rossato (588513)

FASN inhibitors result in decreased ΔΨm and increased superoxide production in melan-a cells. by Franco A. Rossato (588513)

Resveratrol decreases CYP17A1 and CYP21A2 protein expression. by Nesa Marti (3851059)

“…<p>A. Gene expression profiling by qRT-PCR was performed for CYP17, CYP21 and their cofactor POR in H295R cells grown under normal conditions (GM), starvation conditions (SM), metformin (Met) (1mM) treatment and under resveratrol (RSV) (5<u>μM)</u> treatment. …”

BMP type I receptor antagonists decrease Smad 1/5/8 activity in H1299 cells. by Elaine Langenfeld (402034)

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

CD5-2 decreases established CCM lesions in the hindbrain of <i>Ccm2</i>^<i>ECKO</i> mice and lesions in the retina of <i>Ccm2</i>^<i>ECKO</i> mice. by Jia Li (160557)

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Lithium Decreases Glial Fibrillary Acidic Protein in a Mouse Model of Alexander Disease by Christine M. LaPash Daniels (796881)

“…Here we tested whether lithium treatment would decrease levels of GFAP in a mouse model of Alexander disease. …”

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)